Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

  • STATUS
    Recruiting
  • End date
    Dec 31, 2022
  • participants needed
    30
  • sponsor
    Ohio State University Comprehensive Cancer Center
Updated on 15 March 2021

Summary

This phase II trial studies how well letermovir works for the prevention of cytomegalovirus reactivation in patients with hematological malignancies treated with alemtuzumab. Patients receiving treatment with alemtuzumab may experience cytomegalovirus reactivation. Letermovir may block cytomegalovirus replication and prevent infection.

Description

PRIMARY OBJECTIVE:

I. To estimate the rate of cytomegalovirus (CMV) reactivation in patients treated with letermovir at 3 months after completion of alemtuzumab therapy.

SECONDARY OBJECTIVES:

I. To evaluate the tolerability of letermovir in combination with alemtuzumab.

II. To evaluate the efficacy of letermovir for the prevention of clinically significant CMV disease.

III. To estimate the progression free survival of patients in the study population.

IV. To estimate the overall survival of patients in the study population.

EXPLORATORY OBJECTIVE:

I. To evaluate mechanisms of antiviral resistance in letermovir prophylaxis failures.

OUTLINE

Beginning within 7 days of the first administration of standard alemtuzumab, patients receive letermovir orally (PO) (or intravenously [IV] over 1 hour if patient is unable to take PO for an extended period of time) daily on days 1-28. Cycles repeat every 28 days for up to 3 months after the last dose of alemtuzumab in the absence of unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days.

Details
Condition Sezary Syndrome, B-cell prolymphocytic leukemia, Peripheral T-Cell Lymphoma, cutaneous T-cell lymphoma, Lymphoproliferative Disorder, Lymphoproliferative disorders, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, T-Cell Lymphoma, T-Cell Prolymphocytic Leukemia, Lymphocytic Leukemia, Chronic, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Lymphoproliferative disorders, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, leukemia chronic lymphocytic, chronic lymphocytic leukemia (cll), small lymphocytic lymphoma, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Sézary Syndrome, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Treatment Letermovir
Clinical Study IdentifierNCT04312841
SponsorOhio State University Comprehensive Cancer Center
Last Modified on15 March 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Confirmed diagnosis of T-cell or B-cell prolymphocytic leukemia, chronic lymphocytic leukemia, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, or Sezary syndrome
Intent to treat with alemtuzumab. Monotherapy or combination with chemotherapy is allowed
Confirmed seropositivity for CMV IgG (>= 0.7 U/mL) within 1 year of first letermovir dose
Confirmed lack of active CMV infection as evidenced by
Undetectable CMV deoxyribonucleic acid (DNA) by Abbott RealTime CMV in vitro polymerase chain reaction assay (< 50 IU/mL) within 7 days of first letermovir dose AND
Negative CMV IgM (< 30 AU/mL) within 7 days of first letermovir dose
Able to provide informed consent
Life expectancy > 4 months
Eastern Cooperative Oncology Group (ECOG) performance status =< 3
Highly unlikely to become pregnant or impregnate a partner by meeting at least one of the following
A female subject who is not of reproductive potential is eligible without requiring the use of contraception. A female subject who is not of reproductive potential is defined as one who
Has reached natural menopause (defined as 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone [FSH] levels in the postmenopausal range as determined by the local laboratory, or 12 months of spontaneous amenorrhea) OR
Is 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy OR
Has undergone bilateral tubal ligation. Spontaneous amenorrhea does not include cases for which there is an underlying disease that causes amenorrhea (e.g., anorexia nervosa)
A male subject who is not of reproductive potential is eligible without requiring the use of contraception. A male subject who is not of reproductive potential is defined as one whom has undergone a successful defined as
Microscopic documentation of azoospermia OR
A vasectomy more than 2 years ago with no resultant pregnancy despite sexual activity post-vasectomy
A male or female subject who is of reproductive potential agrees to true abstinence or to use (or have their partner use) an acceptable method of birth control starting from the time of consent through 90 days after the last dose of study therapy. True abstinence is defined as abstinence in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., abstinence only on certain calendar days, abstinence only during ovulation period, use of symptothermal method, use of post-ovulation methods) and withdrawal are not acceptable methods of contraception. Acceptable methods of birth control are
Intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom, and vasectomy OR use of appropriate double barrier contraception. Hormonal contraceptives (e.g., birth control pills, transdermal patch, or injectables) are also acceptable

Exclusion Criteria

History of confirmed CMV disease within 1 year of study entry
History of prior allogeneic hematopoietic stem cell transplant
End stage renal disease with creatinine clearance < 10 mL/min as defined by Cockcroft-Gault equation using serum creatinine within 7 days of enrollment
Child-Pugh class C within 7 days of enrollment
Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 times the upper limit of normal (ULN) or serum total bilirubin > 2.5 x ULN
Note: Subjects who meet this exclusion criterion may, at the discretion of the investigator, have one repeat testing done. If the repeat value does not meet this criterion, they may continue in the screening process. Only the specific out of range value should be repeated (not the entire panel)
Both moderate hepatic insufficiency AND moderate renal insufficiency
Moderate hepatic insufficiency is defined as Child Pugh Class B
Moderate renal insufficiency is defined as a creatinine clearance less than 50 mL/min, as calculated by the Cockcroft-Gault equation
Cytopenias are NOT an exclusion criteria in this trial as cytopenias are common in this patient population and letermovir has no known adverse effects on blood counts. Patients will be treated per institutional standard of care with as needed transfusions and growth factor support
Received any of the following drugs within 7 days of enrollment or plans to receive any of the following during the study
Ganciclovir
Valganciclovir
Foscarnet
Acyclovir (at doses > 3200 mg PO per day or > 25 mg/kg IV per day)
Valacyclovir (at doses > 3000 mg PO per day)
Famciclovir (at doses > 1500 mg PO per day)
Cyclosporine A
Pimozide
Ergot alkaloids (ergotamine and dihydroergotamine)
Atorvastatin at doses greater than 20 mg daily
Received any of the following within 30 days prior to enrollment
Cidofovir
CMV hyper-immune globulin
Any investigational CMV antiviral agent/biologic therapy
Infection or underlying disease necessitating ongoing use of prohibited medications
Suspected or known hypersensitivity to active or inactive ingredients of letermovir formulations
Positive at the time of screening for
Human immunodeficiency virus (HIV) with CD4 count < 350\. If HIV positive, must remain on antiretroviral therapy that is not anticipated to interact with letermovir throughout study
Hepatitis B surface antigen or core antibody positivity associated with detectable viral load. For any patient with serologic evidence of prior infection but undetectable viral load, viral load and surface antigen will be monitored every 2 weeks. Those with evidence of reactivation (detectable viral load) will be treated with entecavir or lamivudine. Upon resolution of detectable viral load, the patient will be allowed to continue on trial assuming adequate liver function as defined above. Alternatively, patients may be put on prophylactic entecavir or lamivudine to prevent hepatitis B reactivation at the investigator's discretion
Hepatitis C if no prior or current curative antiviral therapy. For those currently on curative antiviral therapy, they will be allowed on trial if hepatitis C virus (HCV) quantitation is below the limit of detection and adequate liver function as above
Pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from the time of consent through 90 days after the last dose of study therapy
Expecting to donate eggs or sperm starting from the time of consent through 90 days after the last dose of study therapy
Currently participating or has participated in a study with an unapproved investigational compound or device within 28 days, or 5X half-life of the investigational compound (excluding monoclonal antibodies), whichever is longer, of initial dosing on this study. Subjects previously treated with a monoclonal antibody will be eligible to participate after a 28-day washout period
Previous participation in a study using letermovir
Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or would be put at undue risk as judged by the investigator, such that it is not in the best interest of the subject to participate in this study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note